Three-Carbon Linked Dihydroartemisinin-Isatin Hybrids: Design, Synthesis and Their Antiproliferative Anticancer Activity

摘要

Fifteen dihydroartemisinin-isatin hybrids ( 5a-e and 6a-j) linked with three-carbon were designed, synthesized. The antiproliferative activity against lung cancer cell lines including drug-sensitive A549, doxorubicin-resistant A549 (A549/DOX) and cisplatin-resistant A549 (A549/DDP) lung cancer cell lines was tested. The cytotocivity towards normal lung epithelial BEAS-2B cell line was also investigated. From the structure-activity relationship (SAR), it was found that hydrogen bond donors (especially hydroxime and thiosemicarbazide) at C-3 position and electron-withdrawing groups (fluoro and chloro) at C-5 position of isatin moiety were beneficial for the activity. A significant part of them (half maximal inhibitory concentration/IC _(50): 5.72–55.52? μ M) demonstrated considerable antiproliferative activity, and the activity was superior to that of dihydroartemisinin (IC _(50): 69.42–88.03? μ M) and artemisinin (IC _(50): &100? μ M). In particular, two hybrids 6a, e (IC _(50): 5.72–9.84? μ M) were not inferior to doxorubicin (IC _(50): 4.06? μ M) and cisplatin (IC _(50): 9.38? μ M) against drug-sensitive A549 cells and were more potent than doxorubicin (IC _(50): 54.32 and 15.10? μ M) and cisplatin (IC _(50): 19.74 and 66.89? μ M) against multidrug-resistant A549/DOX and A549/DDP lung cancer cell lines. In addition, hybrids 6a, e (IC _(50): &100? μ M) showed no toxicity towards BEAS-2B cells, proving their excellent selectivity profile. Furthermore, hybrid 6a also possessed good stability in mouse and human microsomes, as well as excellent pharmacokinetic properties. Accordingly, hybrid 6a could serve as a promising anti-lung cancer chemotherapeutic candidate for further preclinical evaluations.